Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition
| CLDX Stock | USD 23.85 0.90 3.64% |
Slightly above 57% of Celldex Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Celldex Therapeutics suggests that many traders are alarmed. Celldex Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Celldex Therapeutics' earnings reports, geopolitical events, and overall market trends.
--Data from Phase 1 Study in healthy volunteers presented at CIA Biennial Symposium-- HAMPTON, N.J., Oct. 30, 2025 -- Celldex announced today positive data from the ongoing Phase 1 study of CDX-622, a novel bispecific antibody that targets two non-redundant, complementary pathways implicated in inflammation and fibrosismast cell depletion via stem cell factor starvation and neutralization of the alarmin thymic stromal lymphopoietin . CDX-622 was well t
Read at finance.yahoo.com
 |
Celldex Therapeutics Current Investor Sentiment
Comfort Level 43
Impartial
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Celldex Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Celldex Therapeutics.
News SentimentBullish | Hype SentimentBearish | Insider SentimentWaiting |
Celldex Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Celldex Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Celldex Therapeutics Historical Investor Sentiment
Investor biases related to Celldex Therapeutics' public news can be used to forecast risks associated with an investment in Celldex. The trend in average sentiment can be used to explain how an investor holding Celldex can time the market purely based on public headlines and social activities around Celldex Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Celldex Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Celldex Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Celldex Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Celldex Therapeutics.
Celldex Therapeutics Fundamental Analysis
We analyze Celldex Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Celldex Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Celldex Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Revenue
Revenue Comparative Analysis
Celldex Therapeutics is currently under evaluation in revenue category among its peers. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Celldex Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Celldex Therapeutics stock to make a market-neutral strategy. Peer analysis of Celldex Therapeutics could also be used in its relative valuation, which is a method of valuing Celldex Therapeutics by comparing valuation metrics with similar companies.
Peers
Celldex Therapeutics Related Equities
| GPCR | Structure Therapeutics | 3.82 | ||||
| CELC | Celcuity LLC | 2.55 | ||||
| RCUS | Arcus Biosciences | 2.56 | ||||
| VRDN | Viridian Therapeutics | 2.59 | ||||
| ABCL | Abcellera Biologics | 3.24 | ||||
| EWTX | Edgewise Therapeutics | 3.56 | ||||
| OCUL | Ocular Therapeutix | 4.47 | ||||
| JANX | Janux Therapeutics | 4.67 | ||||
| BHVN | Biohaven Pharmaceutical | 6.06 | ||||
| VERA | Vera Therapeutics | 8.85 |
Additional Tools for Celldex Stock Analysis
When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.